Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RIG-I (Retinoic acid-inducible gene I), MDA5 (Melanoma differentiation-associated protein 5), and PKR (Protein kinase RNA-activated) are essential cytosolic pattern recognition receptors that detect double-stranded RNA (dsRNA), a common signature of viral infection [1][2]. RIG-I and MDA5 are DExD/H-box RNA helicases that, upon binding to specific RNA ligands (short 5'-triphosphate dsRNA for RIG-I and long dsRNA for MDA5), undergo conformational changes and aggregate with the mitochondrial antiviral-signaling protein (MAVS) to initiate a signaling cascade resulting in the production of Type I interferons and pro-inflammatory cytokines [2][3]. PKR is a serine/threonine kinase that, when activated by dsRNA, phosphorylates the alpha subunit of eukaryotic initiation factor 2 (eIF2-alpha), leading to a global inhibition of protein synthesis to halt viral replication and potentially induce apoptosis [4]. In therapeutic contexts, these molecules are targeted by agonists to enhance the immunogenicity of the tumor microenvironment in cancer immunotherapy or to provide broad-spectrum antiviral protection [5]. However, dysregulation of these sensors is linked to autoimmune conditions, such as Aicardi-Goutieres syndrome, where the immune system inappropriately reacts to endogenous nucleic acids [1][3].
Activation of RIG-I and MDA5 triggers the MAVS signaling adapter to induce Type I interferons and pro-inflammatory cytokines; activation of PKR leads to phosphorylation of eIF2-alpha, inhibiting mRNA translation and viral replication.
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Retinoic acid-inducible gene I, Melanoma differentiation-associated protein 5, and Protein kinase RNA-activated (RIG-I / MDA5 / PKR).